

MABION SA (22/2018) Expansion of Mabion S.A.'s Research and Development Centre selected for co-funding

22:49 04/04/2018

Profile: **MABION**

Current report No 22/2018

The Management Board of Mabion SA (the "Company") wishes to announce that on 04 April 2018 it received information that the Company's application for co-funding of a project entitled "Expansion of the Research and Development Centre of Mabion S.A. - research on a new generation of drugs (the "Project") submitted in the course of competition 2.1/2/2017 to Measure 2.1: Support for investments in R&D infrastructure of enterprises of the Smart Growth Operational Programme 2014-2020 has been selected for co-funding. The subject of the project is development of the company's R&D facilities by preparing the necessary infrastructure: the Research and Development Centre building and the purchase of research equipment for the purpose of research on innovative drugs. The designated Research and Development Centre will be used to develop the most cutting-edge generation of biotechnological drugs, – monoclonal antibodies – and prepare them for commercialisation.

The total cost of the Project is estimated at PLN 172.88 million and the recommended value of co-funding is equal to the amount specified in the application, i.e. PLN 63.25 million. The Company will provide information about having concluded the co-funding agreement and the final amount of co-funding (which may differ from the recommended amount) in a separate current report.

More information can be found at: <http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1>